Scott Huennekens

About Scott Huennekens

Scott Huennekens is President and CEO of Volcano Therapeutics. Scott Huennekens has served as our President and Chief Executive Officer and as a member of our board of directors since April 2002. From January 2000 to March 2002, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard University.

Related Entities

Volcano Announces Agreement to Acquire CardioSpectra
66 articles also mentioned Volcano

Volcano Announces Agreement to Acquire CardioSpectra
21 articles also mentioned CardioSpectra

Volcano Announces Acquisition of Axsun Technologies, Inc. for $21.5M
21 articles also mentioned Axsun Technologies

Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
11 articles also mentioned Siemens

Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9 articles also mentioned John Dahldorf

CardioSpectra gets boost in OCT development from Volcano
6 articles also mentioned Thomas E. Milner

Quotes

“ We continued to drive growth in both our intravascular ultrasound (IVUS) and Functional Measurement (FM) businesses, which grew 25 and 51 percent year-over-year, respectively. In the quarter, overall IVUS disposable revenues increased 29 percent versus the prior year, and our FM business increased 50 percent in both the U.S. and Europe...During the quarter, we introduced significant enhancements to our IVUS and FM disposables and our multi-modality console operating software, and commenced the European launch of our VIBE RX Vascular Imaging Catheter. In addition, we completed a number of cases utilizing the latest version of our Optical Coherence Tomography (OCT) catheter and system. ”
In Volcano Reports Record Quarterly Revenues and Profitability; Year-to-Date Revenues Increase 36 Percent
“ We continued to drive growth in both our intravascular ultrasound (IVUS) and Functional Measurement (FM) businesses, which grew 25 and 51 percent year-over-year, respectively. In the quarter, overall IVUS disposable revenues increased 29 percent versus the prior year, and our FM business increased 50 percent in both the U.S. and Europe...During the quarter, we introduced significant enhancements to our IVUS and FM disposables and our multi-modality console operating software, and commenced the European launch of our VIBE RX Vascular Imaging Catheter. In addition, we completed a number of cases utilizing the latest version of our Optical Coherence Tomography (OCT) catheter and system. ”
In Volcano Reports Record Quarterly Revenues and Profitability; Year-to-Date Revenues Increase 36 Percent
“ St. Jude Medical's acquisition of LightLab confirms the validity and potential utility of this leading edge technology...We are planning a best-in-class OCT solution. We currently have CE Mark in Europe on our first generation platform, and we are targeting a release of our second generation platform in Europe early next year. We anticipate that this system will incorporate a smaller catheter, shorter prep time, faster pullback speed, and a longer imaging segment than the current device. ”
In Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
“ We continued to execute on our growth strategies by increasing the installed base of our multi-modality platforms and generating increased market share and utilization for our offerings...Key drivers of our year-over-year growth included a 58 percent increase in intravascular ultrasound (IVUS) disposable revenues in Japan, 46 percent growth in our U.S. functional measurement (FM) disposable sales and increased market penetration in Europe, where IVUS and FM disposable revenues increased 32 percent and 92 percent, respectively. ”
In Volcano Reports 36 Percent Increase in First Quarter Revenues
“ Our technology innovation, market development, clinical and product initiatives have fueled our growth during 2009 and leave us well positioned for a strong 2010 marked by excellent revenue growth and GAAP profitability. ”
In Volcano Reports 44 Percent Increase in Fourth Quarter Revenues
“ Volcano is excited to fortify its commitment to be the leading and most-trusted partner for physicians when addressing patients with complex disease states that require thrombus aspiration. ”
In Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract Thrombus Aspiration Catheter
“ Reaching this milestone as quickly as we have is a clear demonstration of the strong demand for our diverse PCI guidance technology....Despite the challenging healthcare and economic environment in the U.S., Volcano has placed more systems in the past 12 months than at anytime in our history, and by our estimate, capturing more than 70% of all new IVUS systems placed in U.S. hospitals during this period. ”
In Volcano Announces Installed Base Growth Milestone
“ In addition to experiencing a very solid financial performance during the quarter, we completed our transition from our distributor relationship with Goodman to a direct sales effort in Japan and had new data demonstrating the value of our offerings presented at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting. ”
In Volcano Reports 22 Percent Increase in Third Quarter Revenues
“ Angiography alone is not enough and more and more clinical data continues to support that conclusion. ”
In Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
“ Volcano had an excellent quarter with strong growth in our core intravascular ultrasound and functional measurement businesses. ”
In Volcano cuts Q2 loss, revenue increases